Pieris Pharmaceuticals, Inc.

NasdaqCM:PIRS Rapporto sulle azioni

Cap. di mercato: US$18.0m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Pieris Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Steve Yoder

Amministratore delegato

US$1.4m

Compenso totale

Percentuale dello stipendio del CEO43.0%
Mandato del CEO10yrs
Proprietà del CEO0.006%
Durata media del management5.3yrs
Durata media del Consiglio di amministrazione7.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15
Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31
Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15
We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05
Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19
We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22
Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01
Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08
Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01
We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28
How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Yoder rispetto agli utili di Pieris Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$1mUS$585k

-US$25m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$2mUS$565k

-US$33m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$42m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$548k

-US$46m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$48m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$2mUS$535k

-US$37m

Sep 30 2020n/an/a

-US$26m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$2mUS$515k

-US$28m

Sep 30 2019n/an/a

-US$36m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$3mUS$500k

-US$27m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017US$1mUS$450k

-US$18m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 1.36M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 637.96K ).

Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Steve Yoder (48 yo)

10yrs

Mandato

US$1,358,952

Compensazione

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Stephen Yoder
CEO, President & Director10yrsUS$1.36m0.0057%
$ 1.0k
Thomas Bures
Senior VP5.3yrsUS$729.04k0.018%
$ 3.3k
Maria Kelman
Executive Director of Investor Relationsno dataNessun datoNessun dato
Prompong Chaikul
Chief Supply Chain Officer5.2yrsNessun datoNessun dato

5.3yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di PIRS è esperto e expertise (durata media dell'incarico 5.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Stephen Yoder
CEO, President & Director10yrsUS$1.36m0.0057%
$ 1.0k
James Arthur Geraghty
Independent Chairman7.6yrsUS$94.09k0.019%
$ 3.4k
Michael Richman
Independent Director10yrsUS$52.09k0%
$ 0
Christopher Kiritsy
Independent Director8.3yrsUS$72.58k0.019%
$ 3.4k
Peter Kiener
Independent Director6.3yrsUS$65.08k0%
$ 0
Matthew Sherman
Independent Director6.2yrsUS$53.09k0%
$ 0
Ann Barbier
Independent Director6.7yrsUS$52.09k0%
$ 0
Maya Said
Independent Director5.4yrsUS$52.09k0%
$ 0
Ian Adcock
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Oliver Eickelberg
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Fan Chung
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Peter Barnes
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato

7.1yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PIRS sono considerati esperti (durata media dell'incarico 7.1 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/12/16 00:46
Prezzo dell'azione a fine giornata2024/12/13 00:00
Guadagni2024/09/30
Guadagni annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Pieris Pharmaceuticals, Inc. è coperta da 12 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullBaird
Joseph PantginisH.C. Wainwright & Co.
Biren AminJefferies LLC